Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Tenaya Therapeutics, Inc. recently discussed interim data from their MyPEAK-1 trial of the TN-201 gene therapy. This therapy targets MYBPC3-associated hypertrophic cardiomyopathy (HCM). The presentation included insights from key executives and medical professionals involved in the trial.
- ▪Tenaya Therapeutics, Inc. is conducting the MyPEAK-1 trial for TN-201 gene therapy.
- ▪The therapy is aimed at treating MYBPC3-associated hypertrophic cardiomyopathy.
- ▪Key executives and medical professionals participated in the discussion of interim data.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911434-tenaya-therapeutics-inc-tnya-discusses-interim-data-from-mypeakminus-1-trial-of-tnminus-201"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
